Skip to content

Psychedelic-assisted therapy: all studies

Page 175 of 294: studies 1,741 to 1,750 of 2,936, newest first. Back to the psychedelic-assisted therapy overview

Research

Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond

ACS Pharmacology & Translational Science March 7, 2025 Shuai Hu, Cong Lin, Hongshuang Wang et al. 8 citations

Anorexia nervosa (AN) is a severe psychiatric disorder characterized by extreme food restriction, an intense fear of weight gain, and a distorted body image, leading to significant morbidity and mortality. Conventional treatments such as cognitive-behavioral therapy (CBT) and pharmacotherapy often prove inadequate, especially in severe cases, highlighting the need for novel therapeutic...

DOI: 10.1021/acsptsci.5c00094 (opens in new tab) Eating disorders Anorexia nervosa Psychotherapist Bulimia nervosa +1

Adverse Effects and Safety of Antidepressants and Psychedelics for Depression in Cancer: A Systematic Review of Randomized Controlled Trials

Psychoactives March 4, 2025 Renan Massanobu Maekawa, Lorena T. L. Guerra, José Carlos Bouso et al.

Depression is common among patients suffering from cancer, but is often challenging to diagnose due to the overlap of symptoms with cancer and its treatments. Additionally, treating depression in cancer patients is challenging because of the confusion between the adverse effects of antidepressants, cancer treatments, and cancer symptoms. This study aims to evaluate the safety and adverse...

Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use.

Frontiers in Psychology March 4, 2025 Steven Elfrink, Leigh Bergin 11 citations

This paper introduces the hypothesis of Psychedelic Iatrogenic Structural Dissociation (PISD), proposing that psychedelics may reactivate dissociated traumatic material, increasing the risk of psychological destabilization in trauma-exposed individuals. Grounded in structural dissociation theory, this framework suggests that psychedelics can disrupt the balance between daily functioning (the...

Psilocybin therapy might help frontline pandemic workers

The Brown University Psychopharmacology Update March 3, 2025

The stressors that frontline healthcare workers experienced during the COVID-19 pandemic led to widespread burnout, depression, and post-traumatic stress disorder (PTSD). Based on research showing that psychedelic-assisted therapy led to improvement in symptoms of depression in various populations, investigators conducted a randomized clinical trial to evaluate the effects of psilocybin therapy...

Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.

Canadian Medical Association Journal March 2, 2025 Daniel T. Myran, Jennifer Xiao, Nicholas Fabiano et al. 8 citations

Background: Although clinical trials involving psychedelic-assisted psychotherapy have not observed short-term increases in the risk of death, limited data exist on mortality associated with hallucinogen use outside of controlled trial settings. We sought to determine whether people with an emergency department visit or hospital admission involving hallucinogen use were at increased risk of...

DOI: 10.1503/cmaj.241191 (opens in new tab) Full text (opens in new tab) Hallucinogen use Psychedelic use Substance use Drug use +21

The Faithful Response to the Comforting Delusion Objection

Neuroethics March 1, 2025 Adrian Kind 1 citation

Abstract The Comforting Delusion Objection is a central argument in the emerging field of Philosophy of Psychedelics. It posits that while psychedelics may benefit the mental well-being of individuals they also give rise to epistemically unreliable metaphysical beliefs that are incompatible with a naturalist worldview. Assuming naturalism is the correct stance, the result is significant...

DOI: 10.1007/s12152-025-09589-2 (opens in new tab) Full text (opens in new tab) Delusion Neuropsychology Psychoanalysis Epistemology +1

Do undergraduates’ views of psychedelics relate to the context for psychedelic use?

Drug Science, Policy and Law March 1, 2025 Dan Petrovitch, Jason van Allen, Sean M. Mitchell et al. 1 citation

Psychedelic drug policy is changing, both in the USA and internationally. However, psychedelic use is not homogeneous, as there are multiple unique contexts for use, including clinical therapies, naturalistic use, and microdosing. There are notable differences between these contexts regarding emerging evidence for safety, therapeutic efficacy, likely future legality, and more. We compared...

Emerging medications and pharmacological treatment approaches for substance use disorders.

Pharmacology, Biochemistry, and Behavior March 1, 2025 Joel S Raymond, Alexander G Athanasopoulos, Connie J Badolato et al. 7 citations

Medications to treat substance use disorders (SUDs) remain suboptimal or, in the case of stimulants and cannabis, non-existent. Many factors have contributed to this paucity, including the biological complexity of addiction, regulatory challenges, and a historical lack of enthusiasm among pharmaceutical companies to commit resources to this disease space. Despite these headwinds, the recent...

Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials.

JAMA Psychiatry March 1, 2025 Michelle Matvey, Dennis Parker Kelley, Ellen Bradley et al. 12 citations

There is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination of promising clinical trial results, positive media coverage, and the lack of novel pharmacologic treatments for psychiatric disorders in recent decades. However, the field faces a key methodological challenge: masking participants to treatment...

DOI: 10.1001/jamapsychiatry.2024.4312 (opens in new tab) Full text (opens in new tab) Clinical-trials Psychedelics Research-methodology Medical-ethics +1